North America Tissue Engineering Market Developments and Forecast by 2027

The North America Tissue engineering market is expected to reach US$ 12,230.37 million by 2027 from US$ 4,456.95 million in 2019; it is estimated to grow at a CAGR of 13.8% from 2020 to 2027.

Tissue engineering is a procedure used as a blend of material methods and cellular activities. This approach explores the physicochemical and biochemical conditions to replace the biological tissues and strengthen them. It is an innovative technology that works either in isolation or in conjunction with the scaffolds, stem cells, regenerative medicine and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue.

The rising incidence of chronic diseases as well as number of trauma injuries and road accidents are prime factors contributing to the growth of the market for advanced treatment procedures, such as tissue engineering. Road accidents are among the major fatalities in North America region as they cause serious injuries to bones and organs. According to Annual United States Road accidents Statistics, more than 38,000 people die each year in accidents on U.S. roadways. The U.S. traffic fatality rate is 12.4 deaths per 100,000 inhabitants and 4.4 million are serious injured cases are reported which require medical attention. Tissue engineering provide alternative option to surgical reconstruction and transplantation in order to repair damaged tissues.

Stryker Corporation, Organogenesis Inc., Cook Biotech Inc., Integra Life Sciences Corporation are among the major companies in Tissue engineering technology and material. In the U.S., due to an increasing number of COVID 19 infected patients, healthcare professionals and leading organizations are distracting the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. Further, the COVID-19 pandemic spread is also hindering the conduct of clinical trials and drug development, and operations of diagnostic industry in the US. For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits. Moreover, according to a recent survey by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that includes tissue engineering and regenerative medicines as a result of the COVID-19 pandemic. The rapid increase in the number of the infected patients in the US and Canada is likely to result in the slowdown of the market growth in the near future.

Mexico Tissue engineering Market, Revenue and Forecast to 2027 (US$ Mn)

NORTH AMERICATISSUE ENGINEERING MARKET SEGMENTATION

NORTH AMERICA TISSUE ENGINEERING MARKET SEGMENTATION

By Material Type

• Biologically Derived Material
• Synthetic Material
• Others

By Application

• Orthopedic, Musculoskeletal and Spine
• Skin

• Cardiology and Vascular
• Neurology
• Others

By Country

• US
• Canada
• Mexico

Company Profiles

• Stryker Corporation
• Organogenesis Inc.        
• Cook Biotech Inc.
• Integra Life Sciences Corporation
• Acelity L.P.Inc     
• Allergan Plc.       
• Medtronic
• Zimmer Biomet
• Baxter International Inc.
• DePuy Synthes (Johnson & Johnson Services, Inc.)

North America Tissue Engineering Report Scope